Javascript must be enabled to continue!
A Single Point Mutation in the Plasmodium Falciparum 3´-5´Exonuclease Does Not Alter Piperaquine Susceptibility
View through CrossRef
Abstract
Background
The rise in Plasmodium falciparum resistance to dihydroartemisinin-piperaquine (DHA-PPQ) treatment has been documented in the Greater Mekong Subregion with associations with mutations in the P. falciparum chloroquine resistance transporter (pfcrt) and plasmepsin 2 (pfpm2) genes. However, it is unclear whether other genes also play a role with PPQ resistance, such as the E415G mutation in the exonuclease (pfexo) gene. The aim of this study was to investigate the role of this mutation in PPQ resistance by generating transgenic parasites expressing the pfexo-E415G mutant allele.
Methods
Transgenic parasite clones carrying the E415G mutation in pfexo of the B5 isolate were derived by CRISPR-Cas9 gene editing and verified using PCR and gene sequencing. Polymorphisms of pfkelch-13, pfcrt, and pfexo were examined by PCR while the copy number variations of pfpm2 were examined by both relative quantitative real-time PCR and the duplication breakpoint assay. Drug sensitivity against a panel of antimalarials, the ring-stage survival assay (RSA), the PPQ survival assay (PSA), and bimodal dose-response curves were used to evaluate antimalarial susceptibility.
Results
The transgenic line, B5-rexo-E415G-B8, was successfully generated. The PPQ-IC90, %PPQ survival, and the bimodal dose-response clearly showed that E415G mutation in PfEXO of B5 isolate remained fully susceptible to PPQ. Furthermore, growth assays demonstrated that the engineered parasites grew slightly faster than the unmodified parental isolates whereas P. falciparum isolates harbouring pfkelch-13, pfcrt, and pfexo mutations with multiple copies of pfpm2 grew much more slowly.
Conclusions
Insertion of the E415G mutation in PfEXO did not lead to increased PPQ-IC90 and % PPQ survival, suggesting that this mutation is not associated with PPQ resistance and unsuitable to be used as a molecular marker for monitoring PPQ-resistant parasites. The results also highlight the importance of monitoring and evaluating suspected genetic mutations with regard to parasite fitness and resistance.
Springer Science and Business Media LLC
Title: A Single Point Mutation in the Plasmodium Falciparum 3´-5´Exonuclease Does Not Alter Piperaquine Susceptibility
Description:
Abstract
Background
The rise in Plasmodium falciparum resistance to dihydroartemisinin-piperaquine (DHA-PPQ) treatment has been documented in the Greater Mekong Subregion with associations with mutations in the P.
falciparum chloroquine resistance transporter (pfcrt) and plasmepsin 2 (pfpm2) genes.
However, it is unclear whether other genes also play a role with PPQ resistance, such as the E415G mutation in the exonuclease (pfexo) gene.
The aim of this study was to investigate the role of this mutation in PPQ resistance by generating transgenic parasites expressing the pfexo-E415G mutant allele.
Methods
Transgenic parasite clones carrying the E415G mutation in pfexo of the B5 isolate were derived by CRISPR-Cas9 gene editing and verified using PCR and gene sequencing.
Polymorphisms of pfkelch-13, pfcrt, and pfexo were examined by PCR while the copy number variations of pfpm2 were examined by both relative quantitative real-time PCR and the duplication breakpoint assay.
Drug sensitivity against a panel of antimalarials, the ring-stage survival assay (RSA), the PPQ survival assay (PSA), and bimodal dose-response curves were used to evaluate antimalarial susceptibility.
Results
The transgenic line, B5-rexo-E415G-B8, was successfully generated.
The PPQ-IC90, %PPQ survival, and the bimodal dose-response clearly showed that E415G mutation in PfEXO of B5 isolate remained fully susceptible to PPQ.
Furthermore, growth assays demonstrated that the engineered parasites grew slightly faster than the unmodified parental isolates whereas P.
falciparum isolates harbouring pfkelch-13, pfcrt, and pfexo mutations with multiple copies of pfpm2 grew much more slowly.
Conclusions
Insertion of the E415G mutation in PfEXO did not lead to increased PPQ-IC90 and % PPQ survival, suggesting that this mutation is not associated with PPQ resistance and unsuitable to be used as a molecular marker for monitoring PPQ-resistant parasites.
The results also highlight the importance of monitoring and evaluating suspected genetic mutations with regard to parasite fitness and resistance.
Related Results
Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam
Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam
Abstract
Background
Artemisinin-based combination therapies (ACTs) have significantly contributed to reduce Plasmodium falciparu...
Prevalence of Plasmodium Species among Humans and Monkeys at Mole National Park in Northern Ghana
Prevalence of Plasmodium Species among Humans and Monkeys at Mole National Park in Northern Ghana
Malaria is one of the most severe public health problems in Ghana. In developing countries such as Ghana, with high of prevalence of malaria, the procedures for diagnoses and detec...
Development of a Novel Cytochrome b Real-Time PCR Assay for Identification of Plasmodium malariae
Development of a Novel Cytochrome b Real-Time PCR Assay for Identification of Plasmodium malariae
This article aims to establish a novel cytochrome b real-time PCR assay using Taqman probe for identification of P. malariae and its discrimination from other Plasmodium human infe...
Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy
Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy
Abstract
Background
Dihydroartemisinin-piperaquine (DHP) recently showed superior effectiveness over sulfadoxine-pyrimethamine for malaria intermitt...
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
Therapeutic efficacies of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and chloroquine and dihydroartemisinin-piperaquine for uncomplicated Plasmodium vivax infection in Ethiopia
Abstract
Background
Routine monitoring of anti-malarial drugs is recommended for early detection of drug resistance and to inform national malaria t...
A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
A single point mutation in the Plasmodium falciparum 3′–5′ exonuclease does not alter piperaquine susceptibility
Abstract
Background
The rise in Plasmodium falciparum resistance to dihydroartemisinin–piperaquine (DHA–PPQ) treatment has been documented in the Gr...
Prevalence of Plasmodium falciparum identified in people using microscopy, rapid diagnostic test and PCR in the prefecture of Siguiriya/Guinea
Prevalence of Plasmodium falciparum identified in people using microscopy, rapid diagnostic test and PCR in the prefecture of Siguiriya/Guinea
Introduction: Malaria remains one of the leading causes of medical consultations in the tropics. In Guinea, this disease is primarily caused by Plasmodium falciparum. Objective: To...
Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization
Piperaquine resistant Cambodian Plasmodium falciparum clinical isolates: in vitro genotypic and phenotypic characterization
Abstract
Background: High rates of dihydroartemisinin-piperaquine (DHA-PPQ) treatment failures have been documented for uncomplicated Plasmodium falciparum in Cambodia. It ...

